Dissemin is shutting down on January 1st, 2025

Published in

American Heart Association, Arteriosclerosis, Thrombosis, and Vascular Biology, 10(29), p. 1488-1495, 2009

DOI: 10.1161/atvbaha.109.189506

Links

Tools

Export citation

Search in Google Scholar

Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver

Journal article published in 2009 by Fanny Lalloyer, Thomas Åskov Pedersen, Thomas Åskov Pedersen, Barbara Gross, Sophie Lestavel, Saïd Yous ORCID, Emmanuelle Vallez, Jan-Åke Gustafsson, Jan-Åke Gustafsson, Susanne Mandrup ORCID, Catherine Fiévet, Bart Staels, Anne Tailleux
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objective— Bexarotene (Targretin) is a clinically used antitumoral agent which exerts its action through binding to and activation of the retinoid-X-receptor (RXR). The most frequent side-effect of bexarotene administration is an increase in plasma triglycerides, an independent risk factor of cardiovascular disease. The molecular mechanism behind this hypertriglyceridemia remains poorly understood. Methods and Results— Using wild-type and LXRα/β-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers. Interestingly, RNA analysis and Chromatin Immunoprecipitation assays performed in the liver reveal that the in vivo permissive effect of bexarotene on the RXR/LXR heterodimer is restricted to lipogenic genes without modulation of genes controlling cholesterol homeostasis. Conclusion— These findings demonstrate that the hypertriglyceridemic action of bexarotene occurs via the RXR/LXR heterodimer and show that RXR heterodimers can act with a selective permissivity on target genes of specific metabolic pathways in the liver.